GPX4 and renal cell carcinoma: However, combining everolimus with ferroptosis inducers (erastin, which inhibits System Xc−; and RSL3, which targets GPX4) overcomes this limitation: the combination suppresses the mTOR–4EBP1 axis to inhibit RCC cell activity and induce ferroptosis, offering a promising option for drug-resistant mRCC (260).